Irida Kastrati, Ph.D.
Affiliations: | 2009 | University of Illinois at Chicago, Chicago, IL, United States |
Area:
Pharmaceutical ChemistryGoogle:
"Irida Kastrati"Mean distance: (not calculated yet)
Parents
Sign in to add mentorGregory Thatcher | grad student | 2009 | University of Illinois, Chicago | |
(Mechanisms of estrogen carcinogenesis in human breast epithelial cells.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Ekyalongo RC, Flowers B, Sharma T, et al. (2023) SELENOF Controls Proliferation and Cell Death in Breast-Derived Immortalized and Cancer Cells. Cancers. 15 |
Sharma T, Zhang Y, Zigrossi A, et al. (2023) Dimethyl fumarate inhibits ZNF217 and can be beneficial in a subset of estrogen receptor positive breast cancers. Breast Cancer Research and Treatment |
Flowers B, Bochnacka O, Poles A, et al. (2023) Distinct Roles of SELENOF in Different Human Cancers. Biomolecules. 13 |
Semina SE, Alejo LH, Chopra S, et al. (2022) Identification of a novel ER-NFĸB-driven stem-like cell population associated with relapse of ER+ breast tumors. Breast Cancer Research : Bcr. 24: 88 |
Flowers B, Poles A, Kastrati I. (2022) Selenium and breast cancer - An update of clinical and epidemiological data. Archives of Biochemistry and Biophysics. 732: 109465 |
Zigrossi A, Hong LK, Ekyalongo RC, et al. (2022) SELENOF is a new tumor suppressor in breast cancer. Oncogene. 41: 1263-1268 |
Kastrati I, Joosten SEP, Semina SE, et al. (2020) The NFκB pathway promotes tamoxifen tolerance and disease recurrence in estrogen receptor positive breast cancers. Molecular Cancer Research : McR |
Kastrati I, Semina S, Gordon B, et al. (2019) Insights into how phosphorylation of estrogen receptor at serine 305 modulates tamoxifen activity in breast cancer. Molecular and Cellular Endocrinology. 483: 97-101 |
Kastrati I, Brovkovych SD, Stender JD, et al. (2018) Abstract 5242: NFĸB pathway activation is a key determinant of tamoxifen tolerance and recurrence in breast cancer Cancer Research. 78: 5242-5242 |
Smart E, Kastrati I, Frasor J. (2018) Abstract 2158: Inhibition of NFkB restores tamoxifen responsiveness in resistant estrogen receptor positive breast cancer in a syngeneic mouse model Cancer Research. 78: 2158-2158 |